Recurrence of hepatitis C after liver transplantation is associated with increased systemic IL-10 levels

Mediators Inflamm. 2001 Feb;10(1):37-41. doi: 10.1080/09629350124104.

Abstract

Background: Recurrence of hepatitis C after liver transplantation is an almost universal occurrence. T-cell derived cytokines have an important role in the development of liver damage associated with chronic hepatitis C, their post-transplant levels, however, have not been correlated with histologic recurrence of the disease.

Aims: We sought to analyze levels of TNF-alpha, soluble IL-2 receptor, IL-4 and IL-10 at 1 month, 6 months and 1 year after transplantation in 27 patients undergoing transplantation for hepatitis C related end-stage liver disease.

Methods: HCV RNA levels were monitored by a branched-chain DNA signal amplification assay. Diagnosis of recurrent hepatitis was based on 1-year protocol biopsies and on biopsies performed for liver enzyme elevations.

Results: Recurrent hepatitis C was detected in 52% (n=14) of the 27 patients. HCV RNA levels rose over time in all patients regardless of histologic recurrence. TNF-alpha, and IL-4 levels, although elevated, did not show specific patterns over time or in correlation with recurrence. Similarly, the early elevation followed by a gradual decrease over the first year in the amount of soluble IL-2 receptor was not related to histologic recurrence. We observed a significant increase in circulating IL-10 levels over the first year in patients with biopsy-proven recurrence, while patients with no signs of histologic recurrence displayed increased, but steady levels.

Conclusions: These results suggest that while these cytokines are associated with post-transplant recurrence of hepatitis C, their production may be altered by additional factors.

MeSH terms

  • Hepatitis C / diagnosis
  • Hepatitis C / prevention & control*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Interleukin-10 / blood*
  • Interleukin-4 / blood
  • Liver Cirrhosis / prevention & control*
  • Liver Transplantation*
  • Muromonab-CD3 / therapeutic use
  • RNA, Viral / blood
  • Receptors, Interleukin-2 / blood
  • Recurrence
  • Tumor Necrosis Factor-alpha / analysis

Substances

  • Immunosuppressive Agents
  • Muromonab-CD3
  • RNA, Viral
  • Receptors, Interleukin-2
  • Tumor Necrosis Factor-alpha
  • Interleukin-10
  • Interleukin-4